How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Buffer overflow vulnerabilities have driven remote code execution for decades and keep appearing in critical network ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

WHEN ANTHROPIC, an artificial-intelligence lab, debuts on stock markets later this year, it is likely to be one of the biggest initial public offerings in history. That’s because the company’s Claude ...

OpenAI and Broadcom unveiled Jalapeño, a custom AI inference chip designed in nine months. Early tests show 50% cost savings over standard GPUs, with deployment planned for late 2026.

Coinbase co-founder and CEO Brian Armstrong joins Yahoo Finance Executive Editor Brian Sozzi to explain how they're building ...

Nvidia CEO Jensen Huang (R) and SK Group Chairman Chey Tae-won (L) hand out "HBM chip" snacks to reporters during their dinner at a Korean barbecue restaurant in Seoul on June 5, 2026. Nvidia chief ...

The super app is the oldest trick in the technology playbook. OpenAI is staking its IPO valuation on AI to make it work.

Recently, the concept of so-called covenants has received renewed attention as Bitcoin development and protocol discussions underwent a renaissance. Covenants could enable and facilitate a wide range ...

Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Most coverage treats “the Palantir Mafia” as a cute analogy — a nod to the PayPal Mafia that gave us Tesla, LinkedIn, YouTube and Yelp. That framing undersells it. The Palantir Mafia is not analogous ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...